Nuvalent에 대한 매도 수량은 투자자에게 Nuvalent의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Nuvalent (NASDAQ:NUVL) 주식, 공매도 수량 보고

Nuvalent

Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Mid Cap

News

Movers

Trading Ideas

ASND

BLCO

EWTX

NUVL

POWL

지난주 연방준비제도(연준)가 금리를 50bp(베이시스 포인트) 인하하기로 결정하면서 기술, 건설, 산업, 기계 그리고 금융 부문 전반에 걸쳐 주가가 상승했다. 지난주 가장 좋은 실적을 보인 중형주 7종목은 다음과 같다. 여러분의 포트폴리오에 포함되어 있나요?

바우쉬 헬스와 엣지와이즈는 지난주 최고 성과를 보여준 7개 중형주 중 일부 (9월 15일-9월 21일)

CRDO

GRFS

LCID

PRCT

다음은 지난주 큰 폭의 상승세를 보인 8개의 중형주 주식이다. 이 주식들은 여러분의 포트폴리오에 있나요? 1. 루시드 그룹(NASDAQ:LCID)의 주식이 32.91% 급등했다. 이 회사는 루시드 파이낸셜 서비시스(Lucid Financial Services)가 캐나다의 다양한 금융 옵션에 임대를 추가했다고 발표했다. 경제와 금리 인하에 대한 파월 의장의 발언도 심리를 개선했다. 

루시드 및 그리폴스는 지난주 최고 성과를 보여준 8개 중형주 중 일부 (8월 18일-8월 24일)

Nuvalent Inc

Nuvalent GAAP EPS of $1.28

Analyst Charles Zhu from LifeSci Capital maintained a Buy rating on Nuvalent (NUVL – Research Report) and keeping the price target at $110.00. Char...

Nuvalent: Strategic Progress and Pipeline Advancements Solidify Buy Rating

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Prime Medicine, Inc. (PRME – Research Report) and Nu...

Analysts Offer Insights on Healthcare Companies: Prime Medicine, Inc. (PRME) and Nuvalent (NUVL)

Nuvalent, Inc. Class A ( ($NUVL) ) has released its Q3 earnings. Here is a breakdown of the information Nuvalent, Inc. Class A presented to its inv...

Nuvalent Reports Q3 2024 Progress and Financials

In a report released today, Peter Lawson from Barclays maintained a Buy rating on Nuvalent (NUVL – Research Report), with a price target of $100.00...

Barclays Remains a Buy on Nuvalent (NUVL)

Analyst Etzer Darout of BMO Capital maintained a Buy rating on Nuvalent (NUVL – Research Report), boosting the price target to $134.00. Etzer Darou...

Nuvalent's Promising Pipeline and Strategic Advancements Justify Buy Rating

In a report released today, Bradley Canino from Stifel Nicolaus maintained a Buy rating on Nuvalent (NUVL – Research Report), with a price target o...

Nuvalent (NUVL) Receives a Buy from Stifel Nicolaus

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Patterson Companies (PDCO – Research Report), Edwa...

Analysts Offer Insights on Healthcare Companies: Patterson Companies (PDCO), Edwards Lifesciences (EW) and Nuvalent (NUVL)

Nuvalent: Steps Toward That Favorable Entry Point

Nuvalent ( ($NUVL) ) has shared an update. Nuvalent, Inc. has elected Grant Bogle as a new independent director, marking a strategic addition to it...

Nuvalent Elects Grant Bogle as Independent Director

PDCO

PRME

Press Releases

Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655

Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines

Offerings

Nuvalent Announces Public Offering of Common Stock

Nuvalent Announces Pricing of Upsized Public Offering of Common Stock

Nuvalent Announces Closing of Upsized Public Offering of Common Stock

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

From Nuvalent to Nuvectis Pharma: New Report Highlights NXP900's Synergy in NSCLC and Anticipated NXP800 Data Update

Earnings

Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results

Nuvalent to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nuvalent Appoints Grant Bogle to Board of Directors

NVCT

SMMT

Arcellx

Alkermes

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Cytokinetics, Incorporated - Common Stock

Cytokinetics

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Genmab

Grifols, S.A. - American Depositary Shares

Grifols

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Krystal Biotech

Legend Biotech Corporation - American Depositary Shares

Legend Biotech

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Vaxcyte

Radiopharm Theranostics Limited - American Depositary Shares

Radiopharm Theranostics

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

TG Therapeutics

Telix Pharmaceuticals Limited - American Depositary Shares

Comments

Nuvalent

매도 수량

Nuvalent (NASDAQ:NUVL) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌